Monoclonal Antibody Vaccine Therapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer

DISEASE CHARACTERISTICS:

• Histologically confirmed ovarian epithelial, fallopian tube, or peritoneal cancer

  • Stage II-IV
• Initially treated with surgery and at least 1 platinum-based chemotherapy regimen
• Must have relapsed after initial treatment and completed chemotherapy for recurrent disease
• Asymptomatic residual measurable disease on CT scan and/or an elevated CA 125 allowed

• Complete clinical remission allowed, defined by the following criteria:

  • CA 125 no greater than 35 IU/mL
  • No objective evidence of disease by CT scan
  • Normal physical examination

PATIENT CHARACTERISTICS:

Age

• 18 and over

Performance status

• Karnofsky 70-100%

Life expectancy

• At least 3 months

Hematopoietic

• WBC at least 1,500/mm^3
• Platelet count at least 100,000/mm^3
• Hemoglobin at least 10 g/dL

Hepatic

• Bilirubin no greater than 2 times normal
• ALT no greater than 2 times normal
• Alkaline phosphatase no greater than 2 times normal

Renal

• Creatinine no greater than 1.5 times normal

Other

• Not pregnant or nursing
• No potential for child bearing
• Human antimurine antibody negative
• HIV negative
• No other malignancy within the past 5 years except nonmelanoma skin cancer or carcinoma in situ of the cervix
• No active infection
• No known autoimmune disease (e.g., rheumatoid arthritis or ulcerative colitis)
• No known immune deficiency (e.g., hypogammaglobulinemia)
• No known allergy to murine proteins

PRIOR CONCURRENT THERAPY:

Biologic therapy

• At least 6 weeks since prior interferon
• At least 6 weeks since prior immunotherapy or biological response modifiers
• No prior anticancer vaccine

Chemotherapy

• See Disease Characteristics
• At least 3 weeks since prior cytotoxic or investigational chemotherapy

Endocrine therapy

• No concurrent steroids

Radiotherapy

• At least 4 weeks since prior radiotherapy

Surgery

• See Disease Characteristics

Other

• At least 1 week since prior antibiotics
• No concurrent cyclosporine
• No other concurrent immunosuppressive therapy